Trial · NCT04991974
Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine
NCT04991974, Phase 2, Phase 3, Completed, Friends Research Institute, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine. Trials, record NCT04991974. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04991974
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine
- NCT number
- NCT04991974
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 373 participants, actual
- Lead sponsor
- Friends Research Institute, Inc.
- Conditions
- Opioid-use Disorder
- Interventions
- Patient Navigation, Buprenorphine
- First posted
- 2021-08-05
- Last updated
- 2026-05-29
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | OUD treatment entry (number [%] of participants who enter OUD treatment) | 1 month | The primary outcome for the trial is OUD treatment entry by 1 month post-enrollment, defined as admission to a buprenorphine provider (either office-based care or a specialty OUD program), or other licensed OUD treatment program (e.g., methadone, medical detox followed by behavioral treatment). |
| Secondary | OUD treatment retention | 6 months | Treatment retention will be examined as a secondary outcome and will be determined by self-report, with confirmation of admission/discharge dates through provider records if available. |
| Secondary | Opioid use (self-report) | 6 months | Self-reported days of opioid use in the past 30 days |
| Secondary | Opioid use (urine test) | 6 months | Opioid urine drug test |
| Secondary | Cocaine use (self-report) | 6 months | Self-reported days of cocaine use in the past 30 days |
| Secondary | Cocaine use (urine test) | 6 months | Cocaine urine drug test |
| Secondary | OUD diagnostic criteria | 6 months | Opioid use disorder diagnostic criteria will be assessed using items from the OUD criteria checklist derived from the modified World Mental Health-Composite International Diagnostic Interview (WMH-CIDI) items that map to the diagnostic criteria. The time frame of the criteria will be modified to past 30 days to capture acute changes. |
| Secondary | Opioid overdose | 6 months | Participants will be asked at follow-up about non-fatal opioid overdose experiences. We will obtain medical examiner reports to confirm fatal overdoses. |
| Secondary | Sex Risk Behaviors | 6 months | Risky sex behaviors will be gauged by self-report, and include past 90 day frequency of unprotected sex and number of sex partners. |
| Secondary | Drug Risk Behaviors | 6 months | Risky drug injection practices in the past 90-days, gauged by self-report |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38456042 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | GRYCZYNSKI, JAN | FRIENDS RESEARCH INSTITUTE, INC. | NATIONAL INSTITUTE ON DRUG ABUSE | 2019 to 2024 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04991974
GET https://conductscience.org/api/trials/v1/NCT04991974/registered